No CrossRef data available.
Article contents
P.120 Case series: Clinical and genetic spectrum of SCN8A-related disorders in British Columbia
Published online by Cambridge University Press: 05 January 2022
Abstract
Background: Children with pathogenic variations in SCN8A can present with early infantile epileptic encephalopathy-13, benign familial infantile seizures-5 or intellectual disability alone without epilepsy. In this case series, we discuss six children with variants in SCN8A managed at BC Children’s Hospital. Methods: We describe clinical and genetic results on six individuals with SCN8A variants identified via clinical or research next-generation sequencing. Functional consequences of two SCN8A variants were assessed using electrophysiological analyses in transfected cells. Results: Clinical findings ranged from normal development with well-controlled epilepsy to significant developmental delay with treatment-resistant epilepsy. Phenotypes and genotypes in our cohort are described in the table below. Functional analysis supported gain-of-function in P2 and loss-of-function in P4. Conclusions: Our cohort expands the clinical and genotypic spectrum of SCN8A-related disorders. We establish functional evidence for two missense variants in SCN8A, including LoF variant in a patient with intellectual disability, and autism spectrum disorder without seizures.
Table for P.120
Patients | Age/Sex | Development | Age of seizure onset | Epilepsy type | Current antiseizure medication | Seizure frequency | Gene variant/Function | Inheritance |
P1 | 14y/F | Profound GDD | 5m | Infantile spasms, LGS, hyperkinetic movements | Clobazam | Daily | c.1238C>A (p.Ala413Asp) | De novo |
P2 | 6y/F | Normal | 3-7m | Focal epilepsy | Carbamazepine | Seizure free | c.5630A>G (p.Asn1877Ser)/GoF | Paternal |
P3 | 4y/F | Normal | 12m | Focal epilepsy | Clobazam, topiramate | Seizure free | c.4447G>A (p.Glu1483Lys) | De novo |
P4 | 6y/F | GDD, autism | 3y - EEG abnormality only | - | Sodium valproate (discontinued) | No clinical seizure | c.971G>A (p.Cys324Tyr)/LoF, VUS in KCNQ3 | De novo |
P5 | 7y/M | GDD | 5m | Generalized seizures | Ethosuximide, acetazolamide | Daily | c.773C>T (p.Thr258Ile) | De novo |
P6 | 19y/F | Normal | 10y | Focal epilepsy | Carbamazepine | Seizure free | c.986A>G (p.Asp329Gly) | De novo |
Abbreviations: *Father with similar history, y Years, m Months, GDD Global developmental delay, LGS Lennox-Gastaut syndrome, VUS Variant of unknown significance, LoF Loss-of-function, GoF Gain-of-function, EEG Electroencephalogram, F - Female, M - Male, CBD - Cannabidiol
- Type
- Poster Presentations
- Information
- Canadian Journal of Neurological Sciences , Volume 48 , Supplement s3: Canadian Neurological Sciences Federation (CNSF) 2021 Congress , November 2021 , pp. S53
- Copyright
- © The Author(s), 2021. Published by Cambridge University Press on behalf of Canadian Neurological Sciences Federation